Faron Pharmaceuticals Ltd - Turku, Finland-based clinical-stage biopharmaceutical maker - Joins consortium that has received a $1.5 million grant from the US Department of Defense to create preservation strategies for multiple tissue types, including skin, bone, nerves and blood vessels. Tissue preservation is essential for successful transplants, due to time lags in receiving donor tissue. Faron and another industry partner, BMIOrganbank, will work with researchers at two academic centres, Duquesne University’s School of Pharmacy in Pittsburg, Pennsylvania and Atrium Health Wake Forest Baptist Medical Center in Winston-Salem, North Carolina. Faron says the grant specifically will be used to investigate the use of intravenous interferon beta for the prevention of ischemia-reperfusion injury in battlefield victims when using a lifesaving tourniquet for the prevention of excessive blood loss.
Current stock price: 186.55 pence, up 0.8% in London on Tuesday
12-month change: down 25%
Copyright 2024 Alliance News Ltd. All Rights Reserved.
